Journal ArticleDOI
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up
James M. Swanson,Glen R. Elliott,Laurence L. Greenhill,Timothy Wigal,L. Eugene Arnold,Benedetto Vitiello,Lily Hechtman,Lily Hechtman,Jeffery N. Epstein,William E. Pelham,Howard Abikoff,Jeffrey H. Newcorn,Brooke S. G. Molina,Stephen P. Hinshaw,Karen C. Wells,Betsy Hoza,Peter S. Jensen,Robert D. Gibbons,Kwan Hur,Annamarie Stehli,Mark Davies,John S. March,C. Keith Conners,Mark Caron,Nora D. Volkow +24 more
TLDR
Stimulant-naïve school-age children with Combined type attention-deficit/hyperactivity disorder were, as a group, larger than expected from norms before treatment but show stimulant-related decreases in growth rates after initiation of treatment, which appeared to reach asymptotes within 3 years without evidence of growth rebound.Abstract:
Objective: To evaluate the hypothesis of stimulant medication effect on physical growth in the follow-up phase of the Multimodal Treatment Study of Children With ADHD. Method: Naturalistic subgroups were established based on patterns of treatment with stimulant medication at baseline, 14-, 24-, and 36-month assessments: not medicated ( n = 65), newly medicated ( n = 88), consistently medicated ( n = 70), and inconsistently medicated ( n = 147). Analysis of variance was used to evaluate effects of subgroup and assessment time on measures of relative size ( z scores) obtained from growth norms. Results: The subgroup × assessment time interaction was significant for z height ( p z weight ( p z scores significantly >0 at baseline. The newly medicated subgroup showed decreases in relative size that reached asymptotes by the 36-month assessment, when this group showed average growth of 2.0 cm and 2.7 kg less than the not medicated subgroup, which showed slight increases in relative size. Conclusions: Stimulant-naive school-age children with Combined type attention-deficit/hyperactivity disorder were, as a group, larger than expected from norms before treatment but show stimulant-related decreases in growth rates after initiation of treatment, which appeared to reach asymptotes within 3 years without evidence of growth rebound.read more
Citations
More filters
Journal ArticleDOI
ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Mark L. Wolraich,Joseph F. Hagan,Carla C. Allan,Carla C. Allan,Eugenia Chan,Eugenia Chan,Dale Davison,Marian F. Earls,Steven W. Evans,Susan K. Flinn,Tanya E. Froehlich,Tanya E. Froehlich,Jennifer Frost,Joseph R. Holbrook,Christoph U. Lehmann,Herschel R. Lessin,Kymika Okechukwu,Karen Pierce,Karen Pierce,Jonathan D Winner,William Zurhellen,Subcommittee On Children,Hyperactive Disorder +22 more
TL;DR: Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood and can profoundly affect the academic achievement, well-being, and social interactions of children.
Journal ArticleDOI
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Steven R. Pliszka,William Bernet,Oscar G. Bukstein,Heather J. Walter,Valerie Arnold,Joseph H. Beitchman,R. Scott Benson,Allan K. Chrisman,John D. Hamilton,Helene Keable,Joan Kinlan,Jon McClellan,David Rue,Ulrich Schoettle,Saundra Stock,Kristin Kroeger Ptakowski,Jennifer Medicus,Larry Greenhill,Timothy E. Wilens,Thomas J. Spencer,Joe Biederman,Mina K. Dulcan,Lily Hechtman,Caryn L. Carlson,William E. Pelham,James M. Swanson,Russell A. Barkley,Joan P. Gerring,Guy Palmes,Cynthia W. Santos,Catherine Jaselskis +30 more
TL;DR: This practice parameter describes the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) based on the current scientific evidence and clinical consensus of experts in the field.
Journal ArticleDOI
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.
Sandra J J Kooij,Susanne Bejerot,Andrew D. Blackwell,Hervé Caci,Miquel Casas-Brugue,Pieter Jan Carpentier,Dan Edvinsson,John Fayyad,Karin Foeken,Michael Fitzgerald,Veronique Gaillac,Ylva Ginsberg,Chantal Henry,Johanna Krause,Michael B. Lensing,Iris Manor,Helmut Niederhofer,Carlos Nunes-Filipe,Martin D. Ohlmeier,P. Oswald,Stefano Pallanti,Artemios Pehlivanidis,Josep Antoni Ramos-Quiroga,Maria Råstam,Doris Ryffel-Rawak,Steven Stes,Philip Asherson +26 more
TL;DR: This Consensus Statement is one of the actions taken by the European Network Adult ADHD in order to support the clinician with research evidence and clinical experience from 18 European countries in which ADHD in adults is recognised and treated.
Journal ArticleDOI
European guidelines on managing adverse effects of medication for ADHD.
Johnny Graham,Tobias Banaschewski,Jan K. Buitelaar,David Coghill,Marina Danckaerts,Regina Dittmann,Manfred Döpfner,Robert M. Hamilton,Chris Hollis,Martin Holtmann,Martin Hulpke-Wette,Michel Lecendreux,Eric Rosenthal,Aribert Rothenberger,Paramala Santosh,Joseph A. Sergeant,Emily Simonoff,Edmund J.S. Sonuga-Barke,Edmund J.S. Sonuga-Barke,Ian C. K. Wong,Alessandro Zuddas,Hans-Christoph Steinhausen,Eric Taylor +22 more
TL;DR: A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine concerns about the safety of ADHD medications.
Journal ArticleDOI
Attention-deficit/hyperactivity disorder and adverse health outcomes
TL;DR: The current state of knowledge on health-related impairments of ADHD, including smoking, drug abuse, accidental injury, sleep, obesity, hypertension, diabetes, and suicidal behavior, is reviewed, suggesting the need for new avenues of research on mechanisms of association.
References
More filters
Journal ArticleDOI
A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder
P. S. Jensen,L. E. Arnold,Je Richters,Jb Severe,D Vereen,Benedetto Vitiello,E. Schiller,Stephen P. Hinshaw,Gr Elliott,C.K. Conners,Kc Wells,John S. March,James M. Swanson,Timothy Wigal,Dennis P. Cantwell,Hb Abikoff,J Hechtman,Ll Greeenhill,Jh Newcorn,We Pelham,B Hoza,Hk Kraemer +21 more
TL;DR: In this paper, a group of 579 children with ADHD Combined Type, aged 7 to 9.9 years, were assigned to 14 months of medication management (titration followed by monthly visits); intensive behavioral treatment (parent, school, and child components, with therapist involvement gradually reduced over time); the two combined; or standard community care (treatments by community providers).
A Randomized Double-blind Placebo-controlled Trial
TL;DR: The purpose of the present investigation was to evaluate the safety and effectiveness of the antiviral drug amantadine for the treatment of hepatitis C in those who had either previously failed interferon therapy or were not candidates for interferons.
Book
Images of mind
TL;DR: In this article, cognitive psychology and neuroscience are combined to investigate questions about what happens to the brain when we read, write, speak, and visualize, and the authors discuss brain-imaging methods which render certain aspects of thought visible as they occur.
Journal ArticleDOI
Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults
TL;DR: This practice parameter describes treatment with stimulant medication, which carries FDA indications for treatment of attention-deficit/hyperactivity disorder and narcolepsy.
Journal ArticleDOI
3-Year Follow-up of the NIMH MTA Study
Peter S. Jensen,L. Eugene Arnold,James M. Swanson,Benedetto Vitiello,Howard Abikoff,Laurence L. Greenhill,Lily Hechtman,Lily Hechtman,Stephen P. Hinshaw,William E. Pelham,Karen C. Wells,C. Keith Conners,Glen R. Elliott,Jeffery N. Epstein,Betsy Hoza,John S. March,Brooke S. G. Molina,Jeffrey H. Newcorn,Jeffrey H. Newcorn,Joanne B. Severe,Timothy Wigal,Robert D. Gibbons,Kwan Hur +22 more
TL;DR: By 36 months, the earlier advantage of having had 14 months of the medication algorithm was no longer apparent, possibly due to age-related decline in ADHD symptoms, changes in medication management intensity, starting or stopping medications altogether, or other factors not yet evaluated.
Related Papers (5)
A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Steven R. Pliszka,William Bernet,Oscar G. Bukstein,Heather J. Walter,Valerie Arnold,Joseph H. Beitchman,R. Scott Benson,Allan K. Chrisman,John D. Hamilton,Helene Keable,Joan Kinlan,Jon McClellan,David Rue,Ulrich Schoettle,Saundra Stock,Kristin Kroeger Ptakowski,Jennifer Medicus,Larry Greenhill,Timothy E. Wilens,Thomas J. Spencer,Joe Biederman,Mina K. Dulcan,Lily Hechtman,Caryn L. Carlson,William E. Pelham,James M. Swanson,Russell A. Barkley,Joan P. Gerring,Guy Palmes,Cynthia W. Santos,Catherine Jaselskis +30 more
3-Year Follow-up of the NIMH MTA Study
Peter S. Jensen,L. Eugene Arnold,James M. Swanson,Benedetto Vitiello,Howard Abikoff,Laurence L. Greenhill,Lily Hechtman,Lily Hechtman,Stephen P. Hinshaw,William E. Pelham,Karen C. Wells,C. Keith Conners,Glen R. Elliott,Jeffery N. Epstein,Betsy Hoza,John S. March,Brooke S. G. Molina,Jeffrey H. Newcorn,Jeffrey H. Newcorn,Joanne B. Severe,Timothy Wigal,Robert D. Gibbons,Kwan Hur +22 more
The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study
Brooke S. G. Molina,Stephen P. Hinshaw,James M. Swanson,L. Eugene Arnold,Benedetto Vitiello,Peter S. Jensen,Jeffery N. Epstein,Betsy Hoza,Lily Hechtman,Howard Abikoff,Glen R. Elliott,Laurence L. Greenhill,Jeffrey H. Newcorn,Karen C. Wells,Timothy Wigal,Robert D. Gibbons,Kwan Hur,Patricia R. Houck +17 more